Trevi Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Trevi Therapeutics, Inc. (TRVI) on April 6, 2022. The filing discloses the entry into material definitive agreements, specifically a private placement of equity securities and an amendment to an existing loan agreement with Silicon Valley Bank (SVB). The Company is a clinical-stage biopharmaceutical company focused on developing Haduvio for the treatment of chronic cough and prurigo nodularis.
Key Financial Metrics and Capital Structure
- Private Placement Proceeds: Gross proceeds of approximately $55 million.
- Securities Issued: 4,580,526 shares of Common Stock at $1.90 per share and pre-funded warrants to purchase up to 24,379,673 shares at $1.899 per warrant.
- Use of Proceeds: Clinical development of Haduvio for chronic cough in idiopathic pulmonary fibrosis patients, working capital, and general corporate purposes.
- Debt Facility: Existing loan with SVB subject to cash collateralization requirements based on clinical milestones and cash balances.
- Interest Rate Adjustment: Post-transaction interest rate on the SVB loan increases to the greater of the prime rate plus 3.00% or 6.25%.
Material Changes and Agreements
The filing details two primary material changes:
- Private Placement: The Company entered into a Securities Purchase Agreement with purchasers including Frazier Life Sciences, Venrock Healthcare Capital Partners, Fairmount, and New Enterprise Associates (an affiliate). The transaction is expected to close on or about April 11, 2022.
- Loan Amendment: The Company amended its Loan and Security Agreement with SVB. The amendment modifies the conditions triggering the requirement to cash collateralize outstanding loan amounts. Upon the completion of the private placement (defined as the "2022 Equity Event"), the obligation to maintain a $20.0 million minimum cash balance and achieve specific equity fundraising milestones by June 30, 2022, will terminate. Instead, collateralization will be triggered only if positive final data is not received by December 31, 2022, from either the Phase 2b/3 PRISM trial or the Phase 2 CANAL trial.
Guidance, Risks, and Contingencies
The filing contains forward-looking statements regarding the expected closing of the private placement and the use of proceeds. Key risks and contingencies include:
- Closing Conditions: The private placement is subject to customary closing conditions.
- Clinical Trial Uncertainty: Risks regarding the success, cost, and timing of the PRISM and CANAL trials. Failure to receive positive data by December 31, 2022, could trigger cash collateralization of the SVB loan.
- Liquidity and Going Concern: Uncertainties regarding the Company's ability to fund future operations and maintain its Nasdaq listing.
- Registration Rights: The Company agreed to file a registration statement for the resale of securities within 30 days. Failure to maintain the effectiveness of this registration statement could result in liquidated damages of up to 10% of the aggregate amount invested by holders.
Investor Verification Checklist
- Verify the actual closing date of the private placement and the final net proceeds received after deducting placement agent fees and expenses.
- Confirm the status of the SVB loan collateralization requirements following the closing of the equity raise.
- Monitor the progress and interim results of the Phase 2b/3 PRISM trial (prurigo nodularis) and Phase 2 CANAL trial (chronic cough) against the December 31, 2022 deadline.
- Review the filing of the registration statement for the resale of the private placement securities to ensure compliance with the 30-day requirement and avoid liquidated damages.
- Assess the dilution impact of the issuance of 4.58 million shares and 24.38 million pre-funded warrants on existing shareholders.